Form 4: Recursion Pharmaceuticals COO Tina Marriott Executes Stock Option and Sells Shares Under 10b5-1 Plan

Tina Marriott, President and COO of Recursion Pharmaceuticals, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Tina Marriott, the President and COO of Recursion Pharmaceuticals, executed a transaction involving the company's stock on March 21, 2024.
• Marriott exercised a stock option to acquire 8,000 shares of Class A Common Stock at a price of $1.06 per share.
• Simultaneously, Marriott sold 7,390 shares at a weighted average price of $10.6989 and 610 shares at a weighted average price of $11.3361.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan established on March 1, 2023.
• Following these transactions, Marriott directly owns 639,982 shares of Class A Common Stock and holds options to purchase a total of 1,624,049 shares at various exercise prices and expiration dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading plan, so they don't necessarily indicate a change in the executive's outlook on the company. However, any insider selling can create some uncertainty.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it's part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as a significant component.
• The vesting schedules and exercise prices of these options are generally aligned with industry norms to incentivize long-term performance.
• The use of 10b5-1 trading plans is a widespread practice among executives in publicly traded companies, including those in the pharmaceutical sector, such as Amgen, Gilead Sciences, and Biogen, to manage their personal finances while complying with insider trading regulations.

Stakeholder Impact

• Shareholders may react to the news of executive stock sales, although the existence of a 10b5-1 plan should mitigate concerns.
• Employees may be interested in executive compensation and stock ownership.

Key Dates